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Abstract A good staging system should be able to ac- 
curately reflect the natural history of a malignant dis- 
ease, to express the extent of the disease at the time of 
diagnosis, and stratify patients in prognostically dis- 
tinctive groups. The staging system for prostate cancer, 
as it is today, fails to fulfill these requirements. Ap- 
proximately one third of the patients who undergo sur- 
gery for complete excision of prostate cancer in fact do 
not have a localize disease. The incidence of tumor at the 
inked margin may reach 30% for T1 stage and up to 
60% for clinical T2b prostate cancer according to 
comparision with pathologic examination of resected 
specimen. Several concepts have been recently proposed 
as a means of improving the accuracy of the available 
staging system. In this paper, we review current aspects 
of clinical and pathological staging of prostate cancer, 
and the importance of these new concepts on the early 
stages of prostate cancer. 
Prostate cancer (PCa) is a frequent and deadly malig- 
nancy that has become a major health concern for so- 
ciety, physicians, and health organizations worldwide. 
In the United States an estimated 334,500 new cases of 
prostate cancer (PCa) will be diagnosed and 41,800 men 
are expected to perish from this disease in 1997 [68]. For 
this reason, clinicians and researchers have joined efforts 
to improve our understanding of this disease process. As 
a result, the diagnosis and staging of PCa has been in a 
state of evolution over the past two decades. In addition, 
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recent changes in practice patterns have compelled 
urologists not only to provide high quality medical care 
but to do so in a cost-effective manner. Without ques- 
tion, staging is one of the many areas of PCa manage- 
ment that has been modified considerably in recent 
years. 
Clinical staging attempts to reflect the natural history 
of PCa, establish the correct anatomic extension and 
burden of the disease, and stratify patients into distinct 
prognostic groups. An accurate clinical staging, in 
combination with other relevant clinical information at 
diagnosis, allows the urologist to estimate the prognosis 
and develop the best treatment strategy possible. This 
paper discusses the accuracy and usefulness of various 
staging modalities that either have been or are currently 
being used to determine the extension of PCa at the time 
of diagnosis. A review of these staging procedures is 
timely, especially considering that such issues as stage 
migration have resulted from the institution of early 
detection programs [1, 12, 16, 17]. The discussion that 
follows attempts to provide the foundations for the de- 
velopment of a standardized approach to the clinical 
staging of Tlc PCa, which will hopefully lead to the 
elimination of unnecessary or ineffective procedures. We 
believe that the application of a rationalized, consensual 
algorithm for Tlc PCa staging not only is clinically de- 
sirable but should also result in considerable savings for 
the health-care economic resources worldwide. 
Tlc prostate cancer 
In 1992, following a consensus conference, an updated 
TNM staging system was published that is now con- 
sidered the international standard for PCa staging [86]. 
This revision of the previous TNM system introduced a 
new PCa category - stage T l c -  with the purpose of 
recognizing nonpalpable, nonvisible cancers that were 
identified by prostate biopsy (needle biopsy or trans- 
urethral resection of the prostate, TURP) as a result of 
an elevated serum prostate-specific antigen (PSA) level. 
347 
Table 1. Comparison of staging systems for prostate cancer 
American TNM b 
Nonpalpable cancer: 
_< 5% of TURP tissue a 
_> 5% of TURP tissue a 
Cancer detected by biopsy (e.g., elevated PSA) 
Palpable or visible cancer clinically confined within the capsule: 
_< Half of one lobe 
>_ Half of one lobe, but not both lobes 
Both lobes 
Cancer with local extracapsular extension: 
Unilateral 
Bilateral 
Seminal vesicle invasion 
Invasion of bladder neck, rectum, external sphincter 
Invasion of levator muscle or pelvic wall 
Metastatic cancer: 
Single regional lymph node, <2 cm in greatest dimension 
Single regional lymph node, 2-5 cm, or multiple regional lymph nodes <5 cm 
Single regional lymph node, > 5 cm 
Distant metastasis 
Nonregional lymph node(s): 
Bones 
Other sites 











Tla N0 M0 
Tla NO M0 
NO M0 Any G 
NO M0 Any G 
NO M0 Any G 
T2 NO M0 
T3 NO M0 
T4 NO M0 

























M0 Any G 
M 1 Any G 
aDifferent definitions exist for substaging of A1 and A2 cancers 
bN0 or NxM0 for T1 T4 (see above for stage groupings) 
c N x  regional lymph nodes are not assessable, M x  distant metastasis 
There is no equivalent pathologic stage for clinical stage 
T l c  PCa, and such tumors  are invariably up-staged after 
surgery, usually to stage T2 or T3. Today,  at least 25% 
of  the PCa diagnosed in the United States are clinically 
staged as T lc ,  and most  of  these patients undergo an 
extensive, often unnecessary preoperative and intraop- 
erative staging evaluation [e.g., computerized tomo-  
graphy (CT) scan, bone scan, magnetic resonance 
imaging (MRI)  scan, bilateral pelvic lymphadenectomy].  
The American staging system for PCa was introduced 
in 1956 by Whi tmore  [104]. It makes use of  the letters A 
through D to denote stages and was modified by Jewett 
[44] to allow substaging of group B. Recently, similarly 
to the T N M  system, the American system has been 
updated to accommodate  PSA-detected cancers - stage 
B0 (Table 1) [62]. 
Clinical staging modalities 
The most  commonly  used clinical parameters  for deter- 
mining the preoperative extent of  PCa are digital rectal 
is not assessable 
examination (DRE),  PSA concentration, Gleason score 
f rom the biopsy specimen, and radionuclide bone scan. 
Other staging tests that can yield useful information 
about  the extent of  disease in select patients include re- 
verse transcriptase-polymerase chain reaction (RT- 
PCR) assay (molecular staging), seminal vesicle biopsy, 
imaging studies (CT scan and M R I  scan), and bilateral 
pelvic lymphadenectomy.  
Digital rectal examination 
First introduced by Whi tmore  [104] and later popular-  
ized by Jewett [44], D R E  has become the classic method 
for assessing the local extent of  prostate malignancy. 
Although essential, D R E  lacks sensitivity and specificity 
in predicting organ-confined (OC) or non-organ-con- 
fined (NOC) disease. I f  compared  with the final patho- 
logic evaluation of the surgical specimen, D R E  findings 
present a false-negative rate for N O C  disease of  ap- 
proximately 48%, according to several reports [1, 4, 15, 
20, 28, 37, 51, 53, 55, 65, 74, 76, 77, 80, 97, 103, 108]. 
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Partin et al. [74] evaluated 1058 patients, whereby both 
the DRE and radical prostatectomies were performed by 
a single urologist and a single pathologist evaluated the 
surgical specimens. The overall specificity, sensitivity, 
and accuracy of DRE in predicting OC disease was 9%, 
98%, and 57.7%, respectively. Conversely, the negative 
predictive value of DRE for OC disease was in the range 
of 80-93 %, meaning that when DRE indicates an NOC 
cancer it is frequently correct. Similar results were re- 
ported by Ohori et al. [66]. 
Epstein et al. [29] examined the preoperative clinical 
and histopathologic characteristics of 157 men with 
clinical stage Tlc disease, eventually treated with radical 
prostatectomy, and compared these findings with those 
obtained in 439 patients who had their prostates re- 
moved due to a clinical T2 PCa. In all, 16% of the Tlc 
tumors were found to be insignificant tumors confined to 
the prostate gland (volume < 0.2 cm 3, Gleason 
score < 7); 10% had OC tumors with volumes of be- 
tween 0.2 and 0.5 cm 3 , 37% had larger but favorable 
tumors (volume > 0.5 cm or capsular penetration; only 
Gleason score < 7), whereas 37% of the patients had 
either locally or regionally advanced disease (capsular 
penetration, Gleason score_ 7 or positive surgical mar- 
gins, seminal vesicle, and/or lymph node involvement) 
[29]. Oesterling et al. [62] and Noldus and Stamey [57] 
conducted two independent investigations evaluating 
men with Tlc PCa (PSA > 4.0 ng/ml and normal DRE). 
Histopathology study of the specimens revealed that the 
majority of these patients (85% and 87.7% respectively) 
had OC disease. 
In summary, DRE displays a poor performance in 
terms of specificity for OC PCa and sensitivity for NOC 
disease. DRE frequently underestimates the extent of 
disease for PCa, and it is especially inaccurate in the 
staging of Tlc and T2 PCa, many of which are found to 
be T3c on final pathology reports [17, 58, 66, 69]. 
However, in patients with a PSA value of < 4.0 ng/ml 
and a Gleason score of < 7 the presence of a nonsuspi- 
cious DRE defines a patient population with a high 
probability of having localized disease. The positive 
predictive value of DRE for NOC PCa is good; in other 
words, when the DRE indicates a T3a or higher PCa, it 
is most likely an NOC tumor. Despite its limitations, the 
clinical staging of all newly diagnosed PCa starts with a 
carefully performed DRE. 
Prostatic acid phosphatase 
The relationship between PCa and prostatic acid phos- 
phatase (PAP) was first demonstrated more than 50 
years ago [34, 41]. PAP is not prostate-specific, since the 
enzymatic activity of this phosphatase has been identi- 
fied in many body fluids and tissues. The clinical utility 
of PAP is controversial, since a normal PAP serum 
concentration does not guarantee the absence of extra- 
prostatic disease [2, 59, 83]. Stamey et al. [90] analyzed 
378 patients with PCa in an early study designed to 
compare the clinical usefulness of PAP and PSA. They 
found that the serum PSA concentration was elevated in 
122 of 127 men with newly diagnosed, untreated PCa, 
including 7 of 12 patients with unsuspected early disease 
and all of 115 men with more advanced disease. The 
PSA concentration increased with advancing clinical 
stage and was proportional to the estimated volume of 
the tumor. On the other hand, the PAP concentration 
was elevated in only 57 of the patients with PCa and did 
not correlate with tumor volume or with the stage of 
PCa [90]. Burnett et al. [13] found that only 4.6% (21 of 
460) of men with PCa had an elevation in PAP levels, 
and only 1 of 460 patients (0.2%) with a PSA value of 
< 20 ng/ml had an abnormal and uniquely useful PAP 
finding. Considering that an elevated PAP level adds 
little, if any, extra clinical information beyond that of 
total serum PSA concentration, measurement of serum 
PAP (enzyme or immunology assay) has no practical 
role in the staging of Tlc or any other newly diagnosed 
PCa and, therefore, should not be utilized. 
Prostate-specific antigen 
PSA is a chymotrypsin-like serine protease that ulti- 
mately enhances sperm motility by liquefying the semen. 
As its synthesis occurs almost exclusively at the prostate 
gland level, for all practical purposes, PSA is prostate 
gland-specific but not PCa-specific [17, 58, 69]. Once in 
the blood circulation, this protease's function is inhib- 
ited by its binding with alpha-1 antichymotrypsin 
(ACT), resulting in the formation of the PSA-ACT 
complex [58]. Total PSA refers to the sum of all 
immunodetectable species of PSA (free plus complexed 
forms). The predominant bound form of PSA is PSA- 
ACT, which accounts for approximately 90% of all 
complexed forms of PSA [50, 92]. Free PSA possesses at 
least one antigenic epitope that becomes unavailable 
once binding with ACT has occurred. Antibodies tar- 
geted against this free epitope represent the basis for the 
development of immunohistochemistry assays that dis- 
tinguish free from total PSA. 
Lilja et al. [50] and Stenman et al. [92] observed that 
through the quantification of free and complexed forms 
of PSA, they could enhance the specificity of PSA for 
detecting PCa. Following several investigations, it now 
appears that percentage of free PSA values (free PSA/ 
total PSA) are most useful in the range where the total 
PSA concentration is high-normal or only moderately 
elevated (3.0-10.0 ng/ml) [58, 63]. However, to date the 
reported investigations addressing the application of 
percentage of free PSA with the intent of determining 
the clinical stage of PCa have shown that this variable 
does not improve our accuracy in staging PCa [38, 75]. 
Several patient population-based studies have been re- 
ported, demonstrating that the total serum PSA con- 
centration correlates directly with both the clinical and 
the pathologic stage of PCa. In most cases, however, a 
single total serum PSA measurement does not provide 
Table 2. Nomogram for pre- 
diction of final pathologic stage 
for Tic prostate cancer a 
Gleason score PSA (ng/ml) 
0.0-4.0 4.1-10.0 10.1-20.0 > 20.0 
Prediction of organ-confined disease (%) 
2-4 92 82 33 
5 81 71 55 24 
6 69 59 41 22 
7 55 43 24 7 
8-10 - 31 - 3 
Prediction ofestablished capsular penetration (%) 
2-4 22 29 - 50 
5 30 34 40 54 
6 34 38 45 53 
7 40 44 52 67 
8-10 - 48 74 
Prediction ofseminal vesicleinvolvement(%) 
2-4 <1 <1 <1 <1 
5 <1 <1 <i  <1 
6 1 1 1 2 
7 4 5 6 9 
8-10 - 23 - 31 
Prediction oflymph nodalinvolvement(%) 
2~4 <1 1 6 
5 1 1 3 9 
6 2 2 4 8 
7 2 3 7 24 
8-10 5 - 41 
aAdapted from Partin et al. [74] 
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accurate staging information for the individual patient 
[16, 30, 35, 40, 60, 70, 74, 79, 84, 90]. Partin and Oe- 
sterling [58, 69] have reported data that describe the 
application and limitations of total serum PSA for 
screening and detection of PCa as well as its correlation 
with stage, tumor volume, and local or distant metas- 
tases. Efforts are being directed toward establishing 
clinically relevant cutoff points for total serum PSA that, 
by correlating with the above-cited variables, would al- 
low a more accurate prediction of pathologic staging of 
newly diagnosed PCa. 
More recently, Partin and Oesterling [69] described 
total serum PSA staging guidelines for PCa. In all, 7 ~  
80% of men with PSA concentrations of  <4.0 ng/ml 
have pathologically OC PCa, and 50% of men with PSA 
levels of  > 10 ng/ml have extension into the pericap- 
sular adipose tissue [70, 74]. PSA concentration is 
directly related to the volume and stage of the PCa, but 
exact interpretation of  the PSA level is impaired by 
confounding factors that interfere with PSA measure- 
ments (benign prostatic hyperplasia [BPH], prostatitis, 
prostate epithelial component  of the gland) [17, 58, 69, 
92]. Partin et al. [70] have also observed that men with 
more advanced disease have a higher Gleason score and 
tumor volume and produce less PSA per gram of  tumor 
tissue. Kleer et al. [47] and Partin et al. [74] used a lo- 
gistic regression modeling approach and demonstrated 
that the combination of total serum PSA, Gleason score, 
and D R E  provides the best results in terms of predicting 
pathologic stage. F rom these findings, Partin et al. [74] 
constructed predictive probability plots and nomograms 
to help the urologist in the preoperative prediction of 
final pathologic stage for patients with clinically local- 
ized PCa (Table 2). Logistic regression formulas using 
PSA as an independent variable are common in the 
urology literature. Such models are most accurate in 
predicting capsular penetration and are less precise in 
predicting more advanced disease. In summary, total 
serum PSA makes a significant contribution to the 
staging of newly diagnosed PCa, especially when used in 
combination with Gleason scores and D RE findings. 
Molecular staging 
Molecular staging of  PCa correlates the pathologic stage 
of  a localized PCa with RT-PCR (reverse transcription- 
polymerase chain reaction) assay results. The RT-PCR 
technology was first used for PCa detection in 1990 and 
has since provided substantial information for the un- 
derstanding of prostate cancer [101]. The RT-PCR 
method has the ability to detect the presence of a minute 
number of prostate cells in any sample of body tissue. As 
a result, the presence of prostate cancer metastases could 
be detected theoretically at an earlier time, providing the 
basis for a more adequate treatment strategy. The 
presence of distant prostate disease is being investigated 
in the most common sites for metastatic spread (lymph 
nodes and bone marrow) and also in the bloodstream. 
Regardless of the tissue source, intact RN A  is isolated 
from the specimen, and reverse transcription (RT) of 
RNA to cDNA is conducted. Once it has been obtained, 
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the PCR is then used to amplify selected sequences in the 
cDNA. The RT-PCR assay is capable only of identifying 
a prostate cell that has migrated into the vascular system 
(lymphatic or venous) and has survived, because the 
RNA quickly degrades once the cell has died. It also 
should be mentioned that a positive RT-PCR reaction, 
while indicating the presence of prostate cells in the 
blood, does not indicate whether these cells are cancer- 
ous or possess the required ability to establish a meta- 
static site. This phenomenon is a potential shortcoming 
of the RT-PCR technology. 
A recent investigation at Columbia University, using 
RT-PCR for PSA performed on peripheral blood sam- 
ples, has provided data that show potential in helping 
the preoperative staging of patients with PCa [45]. 
It appears that increased assay positivity correlates 
directly with increasing tumor stage. As based on this 
experience, a negative RT-PCR assay ensures OC dis- 
ease in 88% of cases [45]. When combined with other 
clinically relevant parameters (e.g., PSA, DRE, Gleason 
score), the RT-PCR assay has an even better predictive 
ability. With serum PSA levels of < 10 ng/ml and a 
negative RT-PCR index, 81% of cases revealed an OC 
cancer. Conversely, if the serum PSA values is > 10 ng/ 
ml and the RT-PCR index is positive, the patient has a 
90% chance of having positive surgical margins, seminal 
vesicle involvement, or lymph node dissemination of 
cancer. The difference between these two groups 
analyzed by follow-up data demonstrates PSA failure 
rates of 7% for the first group and 43% for the latter 
cohort. A recent pathology review, conducted at the 
same institution, demonstrated that a positive RE-PCR 
result combined with a preoperative needle biopsy 
showing perineural invasion was highly predictive of 
nonlocalized disease. As an isolated variable, RT-PCR 
reached 91% specificity and 51% sensitivity in predict- 
ing extraprostatic disease [67]. 
In summary, these data suggest that RT-PCR, when 
targeted against a prostate-specific marker (e.g., PSA), 
may be useful in differentiating patients with metastatic 
disease from those who do not have advanced PCa. The 
concept of molecular staging is a promising technology 
for early prostate cancer staging, but there is no con- 
sensus regarding its clinical value at present. For this 
reason, the use of RT-PCR should be restricted to the 
field of scientific research and should not yet be used 
routinely in the management of patients with clinically 
localized PCa. 
stage of the PCa [8, 23, 36, 39]. Obtained through a 
sextant biopsy, parameters such as the number of posi- 
tive cores, the tumor location and bilaterality, estima- 
tion of percentages of Gleason grades 4 and 5, and 
perineural and capsular invasion, among others, have 
been evaluated for their contribution to the accurate 
prediction of PCa stage [27, 88]. 
Peller et al. [77] have reported that patients with four 
or more positive cores have a sensitivity of 50%, a 
specificity of 93.2%, and an accuracy of 79% for ex- 
tracapsular penetration. Hammerer et al. [37] evaluated 
a group of 103 men prior to radical prostatectomy; they 
determined the sensitivity and specificity of the number 
of positive sextant cores and the percentage of linear 
involvement in these cores with regard to predicting 
lymph node metastases. Five or more positive cores 
reveal a sensitivity of 66% and a specificity of 94% in 
predicting lymph node involvement. In all, 53 patients 
had fewer than 5 positive cores, and only 3 of them 
(5.6%) had positive lymph nodes. Bostwick et al. [11] 
evaluated 314 men who underwent prostate biopsy and, 
through the use of PSA, biopsy Gleason score, and 
percentage of cancer in the biopsy specimen, were 
capable of reliably predicting capsular penetration and 
final pathologic stage. These findings have been con- 
firmed by other authors as well. Pericapsular fibroadi- 
pose tissue involvement, perineural invasion, and tumor 
in the apex on biopsy are also highly predictive of cap- 
sular penetration and indicate to the surgeon the need to 
sacrifice the ipsilateral neurovascular bundle [1, 7, 42, 80, 
97, 102]. 
Investigations are currently under way, focusing on 
the number of prostate cores per biopsy to be performed 
as a function of the patient's age, prostate volume, and 
critical life-threatening tumor volume [56, 100], i.e., the 
most appropriate number of cores that should be ob- 
tained from a given patient in terms of not only identi- 
fying a significant yet curable PCa but also providing 
sufficient information about the stage of disease. How- 
ever, this must be accomplished in such a manner that 
very small tumors that are not clinically significant are 
not detected. In 1997, all patients should undergo at 
least a systematic sextant biopsy of the prostate due to 
the great amount of information this procedure provides 
for staging and subsequent management. 
Histologic grade 
Biopsy pathology for clinical staging 
Systematic biopsy of the prostate 
A systematic sextant biopsy of the prostate increases the 
detection rate of PCa, regardless of DRE or ultrasound 
abnormalities, and data obtained from the biopsy can 
also be used to predict the tumor volume and pathologic 
The Gleason system is the most commonly used grading 
system in PCa, and it has been shown to correlate with 
the extent of disease and the patient's prognosis [6, 31, 32]. 
The presence of a Gleason score of _>7 or of a Gleason 
grade of 4 or 5 is associated with a less favorable prog- 
nosis [26, 27, 65, 93, 108]. The importance of the Gleason 
system as a predictor of stage is supported by several 
multivariate analyses of prognostic criteria of disease 
extent [4, 9, 14, 26, 27, 43, 54, 62, 7l, 72, 85, 96, 106]. A 
Gleason score of>7 has an accuracy of 58% in predicting 
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OC disease (sextant biopsy) [5]. Nevertheless, the Glea- 
son system has limitations, including the following 
1. The Gleason system is accurate in predicting 
prognosis only on the extreme ends of its scoring spec- 
trum, and the majority of men with PCa (75 80%) have 
intermediate scores (5 7). 
2. The infrequent finding of Gleason scores of be- 
tween 2 and 4 (well-differentiated) or between 8 and 10 
(poorly differentiated). 
3. Gleason scores of 6 and 7 may have quite a dif- 
ferent staging status for the individual patient, depend- 
ing on the presence and percentage of the Gleason 4 
component. 
4. The biopsy Gleason score is usually lower than the 
final postoperative Gleason score (undersampling) 
[25, 52, 71, 74]. 
The biopsy Gleason grading system is a useful tool 
for predicting the stage of disease, but it has limitations 
in terms of accuracy. For this reason it should be com- 
bined with other relevant parameters (PSA and local 
clinical stage) so as to maximize its performance in 
predicting the final pathologic staging. 
Seminal vesicle biopsy 
Seminal vesicle biopsy is recommended for patients with 
a PSA value of > 10 ng/ml, a Gleason score of > 4, and 
a positive DRE (T2b), who are being considered for 
radical prostatectomy to reduce preoperative under- 
staging. Consequently, this approach should not be 
performed on a regular basis for patients with a stage 
Tlc PCa [3, 22, 93, 95, 98]. 
Imaging evaluation 
A series of imaging techniques have been evaluated as 
methods for staging PCa, including intravenous excre- 
tory urography (IVU), transrectal ultrasound (TRUS), 
computerized tomography (CT), magnetic resonance 
imaging (MRI), and radionuclide bone scan. 
Intravenous urography 
Excretory urography is neither useful nor recommended 
for the staging of patients with clinically localized PCa, 
particularly for men with PSA-detected prostate cancer 
(stage Tlc) 
Transrectal ultrasound 
Rifkin et al. [82] conducted a multicenter study to 
evaluate the ability of TRUS to predict capsular pene- 
tration in surgical specimens of patients subjected to 
radical prostatectomy for clinical stage T2 PCa. The 
data collected from 219 patients revealed a specificity of 
46% and a sensitivity of 66%, with an overall accuracy 
of 46% being obtained for the prediction of OC PCa 
(126 of 219 cases). A comparison of TRUS with other 
modalities commonly used to predict OC and NOC PCa 
shows that TRUS does not add any significant or unique 
information in determining the correct PCa stage. This 
observation demonstrates that TRUS has no useful role 
in the clinical staging of PSA-detected PCa. 
CT and MRI scans 
Several investigators have evaluated the ability of CT 
scan, MRI scan, and pedal lymphangiography (PL) to 
stage accurately patients with newly diagnosed PCa. 
These staging studies not only fail to distinguish OC 
from extraprostatic disease but also do not detect ap- 
proximately 50% of pelvic lymph node metastases. For 
this reason the majority of the investigators do not in- 
clude these examinations in the routine staging evalua- 
tion of patients with newly diagnosed PCa. 
CT and MRI scans have been used in several different 
settings in an attempt to identify local extraprostatic 
extension and/or lymph node metastases. Both scans 
have shown a high rate of false-negative and false-pos- 
itive results in the assessment of extraprostatic disease 
[18, 94, 105]. MRI, however, does appear to be more 
precise than CT in evaluating the local extent of PCa, 
but this slight gain in sensitivity and specificity is in- 
sufficient to warrant routine use of this most expensive 
technique. The use of fine needle aspiration (FNA) in 
combination with the CT scan to assess pelvic lymph 
node status has decreased the false-positive rate to 
nearly zero, although the false-negative rate remains at 
the 75% level. The technical inability to combine MRI 
with FNA prevents the use of this methodology in 
evaluation of pelvic lymph nodes. 
Although the CT scan should not be used routinely, 
there is a small subset of patients characterized by a total 
PSA level of > 25 ng/ml and a Gleason score of > 6 for 
whom this imaging modality may be helpful in assessing 
lymph node status. In one study, 13 of 17 positive CT 
scans were found in patients with a PSA level of 
> 25 ng/ml, a Gleason score of > 6, and a positive DRE; 
in this subset of patients, 13 of 71 (18.3%) had lym- 
phatic metastases identified by CT scan [81]. The com- 
bination of this information with the results reported by 
Von Poppel et al. [99], showing a sensitivity of 78% for 
the combined application of the CT scan and FNA for 
identification of positive lymph nodes, defines a useful 
staging recommendation for this subset of patients. 
In summary, patients with a PSA value of > 25 ng/ml 
and a Gleason score of > 6 should undergo a CT scan 
with ENA of any lymph node that is at least 1.0 cm in 
size. Otherwise, a CT or MRI scan should not be rec- 
ommended as a staging procedure. This approach 
should eliminate the use of these imaging studies in over 
90% of men with newly diagnosed PCa. 
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Bone scan 
The radionuclide bone scan has played a traditional role 
in PCa staging, even for clinically localized disease, since 
there is no way to predict which patient will present with 
bone metastases. Nevertheless, PCa management has 
been revolutionized with the advent of  PSA testing, 
making it necessary to review the routine use of bone 
scan for PCa staging. 
During the past few years, several investigations have 
addressed the ability of PSA screening to predict bone 
metastases in men with PCa [19, 61]. The data available 
from these investigations compare PSA results with ra- 
dionuclide bone scan findings, and these findings suggest 
that PSA testing is as reliable as and much more cost- 
effective than the bone scan for most patients. In modern 
urology the use of the radionuclide bone scan as a 
staging procedure for PCa should be restricted to well- 
defined clinical situations. 
Chybowski et al. [19] analyzed 521 randomly selected 
newly diagnosed PCa patients from their data base. 
Prior to treatment, all patients were assessed with D RE 
(local clinical stage), prostate biopsy (tumor grade), se- 
rum PAP and PSA measurement, and radionuclide bone 
scan. The statistical analysis indicated that local clinical 
stage, tumor grade, PAP, and PSA directly correlated 
with a positive bone scan (P < 0.0001). Results were 
plotted on a receiver operating characteristic (ROC) 
curve, and PSA was found to be the best predictor of  
radionuclide bone scan results (Fig. 1). None of  the 
patients with a serum PSA level of  < 15 ng/ml had a 
positive bone scan, and only one man with a PSA value 
of between 10 and 20 ng/ml (18.2 ng/ml) presented with 
a positive examination. The observed false-negative rate 
was zero for PSA values of <10 ng/mi and 0.3% for PSA 
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Fig. 1. Probability plot. Predicted percentage of newly diagnosed, 
untreated prostate cancer patients with positive bone scan (solid line) 
as based on a logistic regression model using the natural logarithm of 
serum PSA concentration. Confidence limits (95%) for predicted 
percentages are based on PSA groupings determined by cutoff points 
of 5, 10, 20, 40, 80, 160, 320, and 640 ng/ml in 521 patients (from 
Chybowsky et al. [19], with permission) 
authors concluded that radionuclide bone scans are not 
necessary in the staging evaluation of men with previ- 
ously untreated PCa who have no skeletal symptom and 
a serum PSA level of <10 ng/ml. In another independent 
study, after reviewing 852 patients with untreated PCa 
and a PSA level of < 20 ng/ml, Oesterling and co- 
workers [61] also found that PSA was capable of pre- 
dicting bone scan findings. Only 7 (0.8%) patients were 
found to have a positive bone scan, and 5 (71%) of them 
presented with symptoms related to the location of the 
positive findings on the bone scan. One patient reporting 
no skeletal symptom and a PSA level of < 10 ng/ml had 
a positive bone scan. On the basis of these results, these 
investigators again concluded that the staging radionu- 
clide bone scan is unnecessary in patients with (1) newly 
diagnosed PCa, (2) a PSA value of _< 10 ng/ml, and (3) 
no skeletal symptom. 
Similarly, Rees et al. [81] determined that elimination 
of the radionuclide bone scan could be safely achieved 
under some PSA- and Gleason-score-based conditions. 
These researchers reviewed 392 patients diagnosed with 
PCa, who had pretreatment serum PSA measurements 
and staging bone scans. None of the patients under the 
following criteria showed evidence of bone metastases: (1) 
a serum PSA level of<5 ng/ml, (2) a Gleason score of<5, 
or (3) a combination of a PSA value of _< 25 ng/ml, a 
Gleason score of  _<7, and a negative D R E  (stage Tlc)  [81]. 
Gleave and colleagues [33] retrospectively analyzed 
pretreatment PSA levels and bone scans on 490 patients 
with recently diagnosed PCa. None of  the 290 patients 
having a PSA value of  <10 ng/mi displayed bone me- 
tastases. Of  the patients with PSA levels of  between 10 
and 20 ng/ml, 4.5% presented with bone metastases. 
The positive predictive value was highest for patients 
with PSA levels of  > 50 ng/ml, among whom 19 of 48 
(40%) patients presented with skeletal metastases. These 
authors also observed a higher rate of bone scan posit- 
ivity in patients with T3 disease (19%) as compared with 
stage T2 disease (1%) or T1 disease (4%). Furthermore,  
they found that patients with poorly differentiated can- 
cers (18%) versus moderately different disease (4%) 
versus well-differentiated disease (1.5%) were more 
likely to have bone metastases. 
In summary, the radionuclide bone scan, although 
the gold standard for the detection of  bone metastases, 
should not be recommended for asymptomatic patients 
with PCa who meet at least one of the following criteria: 
(1) a serum PSA level of  _< 10 ng/ml, (2) a Gleason score 
of  < 5, or (3) a combination of a PSA value of  _< 25 ng/ 
ml, a Gleason score of  < 7, and a negative DRE. 
Bilateral pelvic lymph node dissection 
In 1997 the bilateral pelvic lymphadenectomy remains 
an important and essential procedure in the staging 
evaluation of  newly diagnosed PCa. Reducing the 
number of unnecessary lymph node dissections while 
preserving the quality of  the cancer therapy, however, 
would result in less morbidity for the patient and con- 
siderable financial savings for the health-care system. 
Recent reports indicate that the rate of metastatic 
nodal involvement for localized PCa is presently some- 
where between 3% and 15%, which represents a major 
downward shift from the incidence rate of 30% reported 
in the early 1980s [10, 49, 74, 78, 81, 86, 89]. Kramer and 
colleagues [48] reviewed their data base and reported 
that no patient with a Gleason score of between 2 and 4 
was found to have lymph node metastases, regardless of 
the clinical stage. Conversely, patients with a Gleason 
score of 8-10 had a 93% probability of having lymph 
node involvement. Other authors have clearly demon- 
strated that lymph node status correlates directly with 
clinical stage [24, 64]. Smith and co-workers [87] ob- 
served that patients with stage A1 disease and well-dif- 
ferentiated stage B 1 tumors had an incidence of positive 
lymph nodes of zero and 4%, respectivelY. On the basis 
of these low rates, they suggested that pelvic lymph- 
adenectomy could be avoided in this subset of patients. 
Meanwhile, men with poorly differentiated stage C tu- 
mors should be assumed to have metastatic disease and 
should undergo a pelvic lymph node dissection, since 
93% of the patients evaluated in this study were found 
to have nodal involvement. Zincke and colleagues [107] 
have found that although the biopsy-determined Glea- 
son score directly correlates with the pathologic stage, 
this variable alone is not sufficiently accurate to predict 
lymph node status on an individual basis. 
Recent reports have proposed the combination of 
PSA, clinical stage, and Gleason score as the better 
predictor of metastatic disease to the pelvic lymph 
nodes. Addressing this issue in 1994, Bluestein et al. [10] 
examined the ability of preoperative serum PSA con- 
centration, primary Gleason grade (biopsy specimen), 
and local clinical stage (DRE) to predict accurately the 
pelvic lymph node status of patients with clinically lo- 
calized PCa. The medical records of 1630 patients with 
PCa, who underwent a staging bilateral pelvic lymph- 
adenectomy at the Mayo Clinic between 1988 and 1991, 
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were reviewed. Three distinctively different patient 
groups were identified in this patient population: (1) 1586 
men who underwent bilateral pelvic lymphadenectomy 
and radical retropubic prostatectomy, regardless of the 
node status; (2) 30 patients who underwent pelvic 
lymphadenectomy and no further exploration due to 
metastatic disease; and (3) a group comprising 16 pa- 
tients who underwent staging lymphadenectomy and 
definitive radiation therapy. Through logistic regression 
analysis, serum PSA was found to be the best predictor 
of nodal involvement (P < 0.0001). The predictive power 
of PSA testing could be significantly enhanced by the 
consideration of clinical stage (P<  0.001) and primary 
Gleason grade (P < 0.001). On the basis of these findings 
and variables, the authors developed a statistical model 
allowing the practicing urologist to estimate the relative 
risk of pelvic nodal disease on an individual basis (see 
Table 3, Fig. 2). Given a cutoff point of <_3% as an ac- 
ceptable false-negative rate, 61% of the patients with 
clinical stage T la  T2b may be spared an open or lap- 
aroscopic staging bilateral pelvic lymphadenectomy [10]. 
Using a similar mode, Rees et al. [81] proposed a 
model capable of generating a subset of patients who 
would have a low chance of harboring metastatic lymph 
node disease. On the basis of such a model, the authors 
recommend the elimination of pelvic lymph node dis- 
section in patients with the following criteria: (1) a PSA 
level of < 5 ng /ml ,  (2) a Gleason score not exceeding 5, 
or (3) a combination of a PSA value of < 25 ng/ml, a 
Gleason score of 7 at the most, and a negative DRE. 
Application of these criteria should result in a reduction 
of up to 60% in the number of unnecessary pelvic 
lymphadenectomies carried out in patients with clini- 
cally localized (Tla  T2b) PCa. 
Fine needle aspiration (FNA) of lymph nodes under 
CT guidance is a technique that combines cross-sec- 
tional imaging and aspiration biopsy of enlarged 
(> 1.0 cm) pelvic lymph nodes. It has 70% sensitivity 
and 100% specificity in detecting lymph node metastatic 
disease. Its cost-effectiveness and low morbidity rate 
Table 3. Relationship of serum PSA, primary Gleason grade, and clinical stage with pelvic lymph node status a 
Primary Gleason grade PSA (ng/ml) 
< 2 2~4 4.1-10.0 10.1-20 20.1 50 50.1-100 >100 
1 6 (0) 8 (12.5%) 26 (7.7%) 10 (0) 9 (0) 1 (0) 1 (100%) 
2 45 (0) 63 (0) 202 (2.5%) 113 (8%) 52 (13.5%) 9 (44.9%) 7 (42.9%) 
3 33 (3%) 62 (2.4%) 276 (4%) 176 (19.3%) 121 (16.5%) .22 (32.4%) 15 (60%) 
4 7 (0) 21 (9.5%) 104 (11.5%) 79 (15.2%) 73 (30.4%) 30 (53.3%) 10 (40%) 
5 1 (100%) 2 (50%) 8 (12.5%) 4 (25%) 6 (16.7%) 6 (16.7%) 3 (66.7%) 
Clinical stage 
Tla 5 (0) 3 (0) 7 (0) 1 (100%) 0 (-) 0 (-) 0 (-) 
Tlb 16 (6.3%) 6 (0) 11 (0) 7 (14.3) 5 (0) 1 (0) 1 (0) 
Tlc 5 (0) 7 (0) 88 (0) 53 (3.8%) 40 (10%) 3 (0) 2 (0) 
T2a and T2b 33 (0) 53 (1.4%) 121 (0.8%) 58 (6.9%) 20 (15%) 1 (0) 1 (0) 
T2c 43 (0) 78 (2.6%) 319 (5.3%) 215 (17.7%) 137 (19.7%) 37 (40.7%) 20 (60%) 
T3a 4 (25%) 16 (12%) 69 (17%) 50 (26%) 58 (41%) 26 (53%) 12 (58%) 
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Fig. 2. Probability of positive lymph nodes in patients with clinical 
stage Tla-T2b (A1-B1) prostate cancer, plotted as a function of 
serum PSA concentration and primary Gleason grade. Vertical lines 
indicate 95% confidence intervals for probabilities for serum PSA 
concentrations of 20 and 100 ng/ml. The probability plot was 
determined from logistic regression analysis (from Bluestein et al. 
[10a], with permission) 
warrant its recommendation whenever an enlarged, 
clinically significant lymph node (1.0 cm) can be identi- 
fied on CT scan. The incidence of complications is 
considerably lower following FNA as compared with 
open lymphadenectomy. 
Surgical assessment of  the pelvic lymph nodes can be 
obtained through the use of  two well-established meth- 
ods - open bilateral lymphadenectomy and laparoscopic 
bilateral lymphadenectomy. The first and more tradi- 
tional method, performed in conjunction with radical 
retropubic prostatectomy, is the open pelvic lymph- 
adenectomy. Some potential complications related to 
this surgical procedure include obturator  nerve injury, 
trauma to major vessels, thromboembolic events, 
lymphocele formation, and lymphedema. The lap- 
aroscopic approach, which carries less morbidity than 
the more traditional approach, is more time-consuming 
and, in the short-term analysis, is not cost-effective. The 
complication rate after a laparoscopic lymphadenec- 
tomy is reported to be 15%, according to Kavoussi et al. 
[46]; complications may occur either intraoperatively 
(25%) or postoperatively (75%), and 24% of  them re- 
quire open surgical management. This procedure is 
particularly appealing in the consideration of radical 
perineal prostatectomy or radiation therapy as the 
treatment approach for clinically localized PCa. 
In summary, lymph node dissection via either an 
open or a laparoscopic approach should be indicated in 
the following situations: (1) a prebiopsy serum PSA level 
of  > 5 ng/ml, (2) a poorly differentiated tumor with a 
Gleason score of > 7 [17, 99], (3) five or more positive 
systematic sextant biopsies or a total linear percentage of 
involvement of ___280% [10], (4) a positive seminal vesicle 
Fig. 3. Algorithm for the appro- 
priate staging evaluation of newly 
diagnosed, PSA-detected prostate 
cancer (state Tlc) 
I Abnormal PSA 
I Prostate biopsy 
I T lc  c a n c e r  
I Staging 
I 
t-- 1 Nocaocer I 
I IAnnualORE PSAI 
I 
Staging PSA: _< 5 5 < PSA _< 10 10 < PSA < 25 PSA: > 25 
modality (ng/ml) (ng/ml) (ng/ml) (ng/ml) 
PAP not useful not useful not useful not useful 
TRUS not useful not useful not useful not useful 
MRI scan not useful not useful not useful not useful 
CTscan not not 
recommended recommended may be useful advised 
Bone s c a n  unnecessary  unnecessary  advised advised 
Lympha- unnecessary  r e c o m m e n d e d  strongly advised strongly advised 
denectomy if Gleason > 7 
Fine needle _ _ possible when 
aspiration node >_ 1.0 cm 
RT-PCR investigational investigational investigational investigational 
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biopsy, (5) the presence of  palpably advanced local dis- 
ease of  stage T3 or T4, and (6) the presence of enlarged 
pelvic lymph nodes as determined by pelvic imaging. 
Conclusions 
effective staging evaluation of T l c  PCa in 1997 is pre- 
sented in Fig. 3. The application of a systematic ratio- 
nalized staging protocol  could result in a significant 
impact  on the quality of  care and in more appropriate  
utilization of economic resources in the management  of  
stage T l c  PCa. 
This document  has reviewed a number  of  parameters  
available to and commonly  used by the urologist for 
accurate staging of newly diagnosed, PSA-detected PCa. 
When used alone, however, none of the staging param-  
eters discussed has sufficient accuracy per se in predict- 
ing N O C  disease for the individual patient. DRE-dr iven  
T N M  classification of PCa is the logical initial step of 
clinical staging in all patients. However,  due to its lack 
of sensitivity, specificity, and overall accuracy, it is 
necessary to combine D R E  T-staging with other 
parameters  to improve the performance of  clinical 
staging, ultimately resulting in better therapeutic plan- 
ning. The most  useful and minimally required variables 
to be associated with D R E  are total serum PSA con- 
centration, Gleason score, and other findings f rom the 
systematic prostate biopsy. Partin et al. [74] have re- 
ported nomogram tables based on total serum PSA, 
Gleason score, and local clinical stage that provide 
predictive probabilities for OC disease, N O C  cancer, 
seminal vesicle invasion, and lymph node metastases 
(Table 2). The systematic sextant biopsy of  the prostate  
can add a number  of  staging parameters  that, once 
combined into a biopsy-based staging system, may  be- 
come useful in therapeutic planning. 
The indication for seminal vesicle biopsy remains 
controversial. Available data suggest that  it may be 
useful in staging patients with large palpable tumors 
(T2b-c).  A positive seminal vesicle biopsy associated 
with findings such as a PSA value of  > 20 ng/ml, a high 
Gleason score (8-10), and five or more positive biopsy 
cores indicates a poor  prognosis. Nevertheless, on a 
regular basis this procedure should not be recommended 
or performed in a patient with stage T l c  PCa. 
Radiography studies play a very restricted role in the 
staging of  the newly diagnosed PCa. The available data 
indicate that imaging studies (TRUS,  CT scan, and M R I  
scan) are not sufficiently accurate to determine the local 
extent of  this disease. Assessment of  lymph node status 
is cost-effective only for patients at high risk for pelvic 
lymph node metastases. Radionuclide bone scan evalu- 
ation is necessary for the man with newly diagnosed PCa 
only if the total serum PSA level exceeds 10 ng/ml or if 
he has skeletal symptoms.  
The algorithm developed by Bluestein and co-work- 
ers [10] to assess the risk of  lymph node metastases is 
valuable for safely deciding which patients do not re- 
quire a lymph node biopsy or formal pelvic lymph node 
dissection. 
There is no doubt  that  more efforts are necessary 
toward improving the currently available multivariate, 
clinical staging method for stage T l c  PCa. A consensual 
rationalization of what is felt to be an appropriate,  cost- 
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